The approval expands the indication of pirtobrutinib to patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma with no known 17p deletion.
News|Videos|December 19, 2017
Updates in Splenic and Nodal Marginal Zone Lymphoma
Author(s)Catherine Thieblemont, MD, PhD
This video reviews updates on the treatment and biology of splenic and nodal marginal zone lymphoma.
Advertisement
In this video, Catherine Thieblemont, MD, PhD, of Hopital Saint-Louis in Paris, discusses updates on the treatment and biology of splenic and nodal marginal zone lymphoma.
Thieblemont gave a presentation on this topic during an education session at the 2017 American Society of Hematology (ASH) Annual Meeting and Exposition, held December 9–12 in Atlanta.
Advertisement
Related to this article
“No one should be excluded from any clinical trial,” said Paul G. Rubinstein, MD, regarding patients with HIV-associated cancers in cooperative group studies.
Veronika Bachanova, MD, PhD, discussed how the favorable safety profile of CAR natural killer cell therapies may come with trade-offs in persistence and response durability.
Adding fixed-duration epcoritamab to R-CHOP reduced the risk of progression or death by 51% in patients with newly diagnosed DLBCL.
Paul Rubinstein, MD, discussed how cooperative groups are expanding CAR T and bispecific antibody research for patients with HIV-associated lymphoma.
Developers have resubmitted the biologics license application for tabelecleucel following feedback from a Type A meeting in April 2026.
“To me, the biggest differentiator might be how the patient wants to experience care,” said Krish Patel, MD, on treatment options for patients with lymphoma.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Atezolizumab/Chemo for Stage III dMMR Colon Cancer
2
Novel Cancer Vaccine Plus Temozolomide Miss Primary End Point in Glioblastoma
3
FDA Approves Tucatinib Combo as Maintenance in HER2+ Breast Cancer
4
Iberdomide Combination Doubles PFS vs SOC Therapy in R/R Multiple Myeloma
5